

**DATINVEST INTERNATIONAL LTD.**  
Suite 918, 1030 West Georgia Street  
Vancouver, British Columbia  
V6E 2Y3

## **NEWS RELEASE**

### **DATINVEST TERMINATES DEFINITIVE AGREEMENT WITH EXXEL PHARMA**

March 19, 2019 – Vancouver, British Columbia – Datinvest International Ltd. (TSXV: DAI.H) (the “**Company**”) announces that the definitive amalgamation agreement entered into with Exxel Pharma Inc. (“**Exxel Pharma**”) has been terminated effective immediately. In connection with the proposed acquisition of Exxel Pharma, no funds were advanced to Exxel Pharma or any of its related parties and the Company did not assume any contingent liabilities or guarantees. For further information concerning the definitive amalgamation agreement entered into with Exxel Pharma, readers are encouraged to review the Company’s news release of June 11, 2018.

At this time, management of the Company anticipates initiating a review of potential strategic acquisition opportunities for the Company and will provide further information on this review as it progresses.

The Company has requested that trading in its common shares resume on the TSX Venture Exchange, and will issue a further news release once the effective date for the resumption has been confirmed.

For further information, contact Emily Davis, Corporate Secretary of the Company, at 604.628.5616 or [emily@sentinelcorp.ca](mailto:emily@sentinelcorp.ca).

On behalf of the Board,

**Datinvest International Ltd.**

Sean Davis, Chief Executive Officer

*Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.*